

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**February 1, 2006**  
**MINUTES**

**1. Call To Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, February 1, 2006.

**2. Welcome**

Dr. LaCroix called the meeting to order and welcomed members, guests, and staff.

Jim Bracewell welcomed members and guests. Mr. Bracewell mentioned that various informational items about the South Carolina Pharmacy Association (SCPhA) were available and that the Pharmacy Industry Advisory Council's next meeting is scheduled for March 1<sup>st</sup>. Also, Mr. Bracewell announced that he would be leaving the SCPhA in the summer of 2006 since he had accepted a similar position in Georgia.

Following these introductory remarks, Dr. LaCroix opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Edward M. Behling, M.D.	Joseph A. Horvath, M.D.	Thomas Phillips, R.Ph.
Gregory V. Browning, M.D.	Jerome E. Kurent, M.D.	Deborah J. Tapley, R.Ph.
Kelly Jones, Pharm.D.	Robin K. LaCroix, M.D.	Harry H. Wright, M.D.
	James M. Lindsey, M.D.	

**DHHS Staff Present:**

James M. Assey, R.Ph.  
Marion Burton, M.D.  
Wanda Metts  
Byron Roberts, J.D.  
Deirdra Singleton, J.D.  
Caroline Sojourner, R.Ph.

**Other Representation:**

First Health Services. – Mary Roberts, R.Ph.  
Pharmaceutical Industry Representatives

#### 4. Discussion Topics

##### A. Committee Meeting Minutes, Wednesday, November 1, 2005.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. Those minutes were approved unanimously.

##### B. Public Comment

The rules for public comment were outlined. Dr. LaCroix instructed the speakers that presentations would be limited to three minutes. The following speakers (in the following order) discussed the drugs listed below:

	<b>Company</b>	<b>Speaker</b>	<b>Drug</b>
1)	Bristol Myers Squibb	Ken Frisar, Pharm. D.	Tequin®
2)	Schering Plough	Brian Woolhouse	Avelox®
3)	Oscient Pharmaceuticals	Sean Fuller, M.D.	Factive®
4)	Ortho McNeil Pharmaceuticals	Kevin W. Shea, M.D., F.A.C.P.	Factive®

In response to the Committee's request for a sub-specialist to provide a non-biased overview of quinolones, Dr. Marion Burton introduced Dr. Divya Ahuja, M.D. Dr. Ahuja, Assistant Professor of Clinical Internal Medicine Infectious Diseases at the USC School of Medicine, delivered a PowerPoint presentation on quinolones and spoke to the Committee for about twenty minutes.

Following the period of public comment, Dr. LaCroix thanked each speaker for his or her individual presentation. Dr. LaCroix also reminded Committee members of the requirement to disclose any potential conflicts of interest at this time, prior to the discussion of PDL selections.

##### C. Drug Class for Re-Review

Mary Roberts, R.Ph., First Health Corporation led the discussion for the following drug class:

#### Quinolone Antibiotics

The P&T Committee voted to submit the following recommendations to DHHS:

No PA Required "Preferred"	PA Required
<b>QUINOLONES – SECOND GENERATION</b>	
CIPROFLOXACIN OFLOXACIN	MAXAQUIN® NOROXIN®
<b>QUINOLONES – THIRD GENERATION</b>	
AVELOX® LEVAQUIN®	TEQUIN®
<b>QUINOLONES – FOURTH GENERATION</b>	
FACTIVE®	

Committee members requested that a notation be added on the PDL to indicate that Avelox® is not recommended for use in urinary tract infection.

P&T Committee members suggested that it would be helpful if medications were listed on the PDL with relative cost information to assist prescribers in making cost effective decisions.

Members of the P&T Committee commented on their appreciation of Dr. Ahuja's scientific discourse on quinolones.

## 5. Old Business

Dr. LaCroix reminded Committee members that the recommendations of the P&T Committee will be submitted to DHHS for approval. Final decisions will be communicated to providers in a Medicaid bulletin.

Committee members discussed the potential for conflict of interest when approached by members of the pharmaceutical industry in regards to PDL status of drugs.

P&T Committee members were reminded that all have signed a Conflict of Interest statement that includes the following: "...A conflict of interest would also arise if a Committee member were to entertain individual lobbying or marketing, or partake in any other activity/discussions with pharmaceutical manufacturers or their representatives that would call into question their impartiality in recommending drugs to be included or excluded from the enhanced prior approval program."

Members agreed not to interact with pharmaceutical industry representatives for the sole purpose of discussing PDL status of drugs.

The following statement will be posted on the web site and will be included on the agenda for future meetings.

“Members of the pharmaceutical industry are requested to submit information regarding potential PDL drugs to the South Carolina Department of Health and Human Services and should not directly contact or send mailings to P&T Committee Members or their staff regarding the PDL status of drug products. ~~Committee members are prohibited from contact with pharmaceutical representatives in advance of an upcoming P&T Committee meeting where the representative’s company’s product or issue will be discussed.~~<sup>22</sup> Amended 5-3-06 to delete previous sentence and insert: Committee members must not discuss issues regarding PDL status of drugs with members of the pharmaceutical industry.

**6. New Business**

Dr. LaCroix mentioned that she hoped to hear discussion at the next P&T meeting in regard to the impact of Medicare Part D on South Carolina’s Medicaid program.

Wanda Metts was introduced as a new DHHS staff member who will provide administrative support for the P&T Committee meetings.

**7. Resolved Items**

Recommendations regarding PDL status for drugs in the following drug classes were approved for submission to DHHS:

Quinolone Antibiotics

**8. Closing Comments**

Dr. LaCroix thanked the Pharmacy Association for hosting the P&T Committee meeting and announced that the next P&T Committee meeting will be held at the South Carolina Pharmacy Association office on Wednesday, May 3, 2006.

**9. Adjournment**

The meeting adjourned at 6:30 p.m.